Jose Rosa-Valero

Cordoba, AN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice.

The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice.

Journal: The Prostate

Published: December 12, 2022

Serum biomarkers for diagnosis and characterization of prostate cancer.

Serum biomarkers for diagnosis and characterization of prostate cancer.

Journal: Archivos espanoles de urologia

Published: March 25, 2022

Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?

Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?

Journal: Diagnostics (Basel, Switzerland)

Published: June 17, 2021

Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance.

Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance.

Journal: Korean journal of radiology

Published: July 02, 2020

Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.

Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.

Journal: BMJ open

Published: November 15, 2019

Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer.

Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer.

Journal: Journal of clinical medicine

Published: August 20, 2019

CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.

CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.

Journal: British journal of cancer

Published: October 06, 2018

Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.

Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.

Journal: Journal of cellular and molecular medicine

Published: September 11, 2018

Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.

Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.

Journal: Journal of cellular and molecular medicine

Published: May 28, 2018

New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience.

New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience.

Journal: Urology

Published: March 23, 2017

The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.

The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.

Journal: Molecular cancer

Published: November 01, 2016

European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance.

European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance.

Journal: Urology

Published: September 19, 2016

Showing 1-12 of 17

Last Updated: 09/26/2026